Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

59.79 +2.17 (+3.77%)
Streaming Delayed Price Updated: 1:47 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
86 87 Next >
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Can Biotech Stocks Survive The Precarious Macro? ↗
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
News headline image
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond ↗
Via The Motley Fool
News headline image
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average ↗
Via The Motley Fool
Topics Stocks
News headline image
Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Biotech And Healthcare Stocks Poised For Gains Ahead ↗
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
This Unpopular Dividend Stock Is a Buy ↗
Via The Motley Fool
News headline image
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
From Bristol Myers Squibb
Via Business Wire
News headline image
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
News headline image
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
News headline image
Peering Into Bristol-Myers Squibb's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy Early in 2025 ↗
Via The Motley Fool
News headline image
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
News headline image
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
News headline image
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
From Arsenal Biosciences
Via GlobeNewswire
News headline image
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
News headline image
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb. 
Via Benzinga
Topics ETFs
News headline image
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade ↗
Via The Motley Fool
News headline image
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City ↗
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape. 
Via Benzinga
News headline image
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
News headline image
Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential. ↗
Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout. 
Via Chartmill
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
86 87 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.